HPB-092

N/A

Report date: 2024/12/30 10:35:33
NME

Base Information

Drug NameHPB-092
Drug Alias NameHPB-092
ClassificationSmall molecules
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitorsInterleukin-1 receptor-associated kinase 1 inhibitors
TargetsTyrosine-protein kinase receptor FLT3Interleukin-1 receptor-associated kinase 1
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPolymed Biopharmaceuticals Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesPolymed Biopharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A